multiple dose studies [Design Issues]

posted by Loky do – Egypt, 2024-03-04 11:27 (46 d 23:12 ago) – Posting: # 23892
Views: 771


I have a solifenacin succinate/tamsulosin HCl bioequivalence study, I will perform a multiple-dose study for tamsulosin modified release for Europe, I'm a little confused about the planned washout for this study as there are no enough public assessment reports for the combination, should I take in account the solifenacin washout period also or to design on tamsulosin only is enough (i.e one-week washout between 2 periods from last dose)

thanks in advance

Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,988 posts in 4,825 threads, 1,658 registered users;
92 visitors (0 registered, 92 guests [including 5 identified bots]).
Forum time: 11:40 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz